HRT and cancer risks

Maturitas

Volumn 43, Issue SUPPL., 2002, Pages

  Schneider, Hermann P G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cancer; Carcinogen; HRT

Indexed keywords

CARCINOGEN; CYPROTERONE ACETATE; DESOGESTREL; DNA; DYDROGESTERONE; ENZYME; ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; NORGESTREL; PROGESTERONE; SEX HORMONE; TOXIN;

ADENOMA; BREAST DUCT; BREAST TUMOR; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; COLON CARCINOMA; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFECT; ENDOMETRIUM CARCINOMA; ENZYME POLYMORPHISM; EXPOSURE; GENOTOXICITY; HEALTH STATUS; HOMEOSTASIS; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; METABOLISM; METABOLITE; OVARY CARCINOMA; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; TISSUE DIFFERENTIATION; TISSUE GROWTH; TISSUE SPECIFICITY; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA;

EID: 0037200655     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0378-5122(02)00147-0     Document Type: Review

References (90)

1. International Agency for Research on Cancer, In: Monographs on the evaluation of carcinogenic risks to humans, Lyon, France: IARC, Suppl 7, 1987. pp. 280-85.
2. Inoh A., Kamiya K., Fujii Y., Yokoro K. Protective effects of progesterone and tamoxifen in estrogen-induced mammary carcinogenesis in ovariectomized W/Fu rats. Jpn. J. Cancer Res. 76:1985;699-704.
3. Gold L.S., Slone T.H., Stern B.R., Manley N.B., Ames B.N. Rodent carcinogens: setting priorities. Cience. 258:1982;261-265.
4. Siiteri P.K., Nisker J.A., Hammond G.L. Hormonal basis of risk factors for breast and endometrial cancer. Iacobelli S., King R.J.B., Lindner H.R., Lippman M.E., Hormones and cancer. 1980;499-505 Raven Press, New York.
5. Key T.J.A., Pike M.C. The dose-effect relationship between 'unopposed' estrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer. 57:1988;205-212.
6. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women, J. Natl. Cancer Inst. 1995;1076-82.
7. Bernstein L., Ross R.K., Pike M.C., Brown J.B., Henderson B.E. Hormone levels in older women: a study of postmenopausal breast cancer patients and healthy population controls. Br. J. Cancer. 61:1990;298-302.
8. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
9. Liehr J.C. Is estradiol a genotoxic mutagenic carcinogen. Endocr. Rev. 21:2000;40-54.
10. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens, Cancer Res. 15(60):235-37.
11. Kerlan V., Dreano Y., Bercovici J.P., Beaune P.H., Floch H.H., Berthou F. Nature of cytochrome P450 involved in the 2/4-hydroxylation of estradiol in human liver microsomes. Biochem. Pharmacol. 44:1992;1745-1756.
12. Weisz J. Metabolism of estrogens by target cells. Diversification and amplification of hormone action and the catecholestrogen hypothesis. Hochberg R., Naftolin F., New biology of steroid hormones. 1991;201-212 Raven Press, New York.
13. Bui Q.D., Weisz J. Monooxygenase mediating catecholestrogen formation by rat anterior pituitary is an estrogen-4-hydroxylase. Endocrinology. 124:1988;1085-1087.
14. Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., Sutter T.R. 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. 93:1996;9776-9781.
15. Castagnetta L.A., Granata O.M., Arcuri F.P., Polito L.M., Rosati F., Cartoni G.P. Gas chromatography/mass spectrometry of catecholestrogens. Steroids. 57:1992;437-443.
16. Roy D., Liehr J.G. Temporary decrease in renal quinone reductase activity induced by chronic administration of estradiol to male Syrian hamsters. J. Biol. Chem. 263:1988;3646-3651.
17. Tsukamoto A.S., Grosschedl R., Guzman R.C., Parslow T., Varmus H.E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 55:1988;619-625.
18. Bocchinfuso W.P., Hively W.P., Couse J.F., Varmus H.E., Korach K.S. An MMTV-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-α Cancer Res. 59:1999;1869-1876.
19. Gusberg S.B., Kaplan A.L. Precursors of corpus cancer. Am. J. Obstet. Gynecol. 87:1963;662.
20. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
21. Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer. 56:1985;403-412.
22. Jackisch C., Schneider H.P.G. Biological effects of estrogens and progestogen on human breast cancer carcinogenesis. Menopause Rev. 2:1997;26-34.
23. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 2:1896;104-107.
24. Schneider H.P.G., Jackisch J. Reproductive cancer and hormone replacement. Fischl F.H., Menopause andropause. 2001;173-204 Krause and Pachernegg, Gablitz.
25. Bush T.L., Whiteman M., Flaws J.A. Hormone replacement therapy and breast cancer: a qualitative review. Obstet. Gynecol. 98:2001;498-508.
26. Speroff L. Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports, Climacteric 2000;3.3-12
27. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15:1993;17-35.
28. Russo J., Russo I.C.H. Towards a physiological approach to breast cancer prevention. Can. Epid. Biomed. Prev. 3:1994;353-364.
29. Clemons M., Gloss P. Estrogen and the risk of breast cancer. New Engl. J. Med. 344:2001;276-285.
30. van Landeghem A.A.J., Poortman J., Nabuurs M., Thijssen J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
31. Miyoshi Y., Anto A., Shiba E., Taguchi T., Tamaki Y., Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer. 94:2001;685-689.
32. Reed M.J., Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr. Rev. 18:1997;701-715.
33. Reed M.J., Owen A.M., Lai L.C., Coldham N.G., Ghilchik M.W., Shaikh N.A., James V.H.T. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int. J. Cancer. 44:1989;233-237.
34. Blankenstein M.A., Maitimu-Smeele I., Donker G.H., Daroszewski J., Milewicz A., Thijssen J.H.H. Tissue androgens and the endocrine autonomy of breast cancer. J. Steroid Biochem. Mol. Biol. 43:1992;167-171.
35. Lipton A., Santner S.J., Santen R.J., Harvey H.A., Feil P.D., White-Hershey D., Bartholomew M.J., Antle C.E. Aromatase activity in primary and metastatic human breast cancer. Cancer. 59:1987;779-782.
36. Harada N., Utsumi T., Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc. Natl. Acad. Sci. USA. 90:1993;11312-11316.
37. Zhou C., Zhou D., Esteban J., et al. Aromatase gene expression and its exon I usage in human breast tumors: detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J. Steroid Biochem. Mol. Biol. 59:1996;163-171.
38. Yue W., Wang J.P., Hamilton C.J., Demers L.M., Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 58:1998;927-932.
39. Perel E., Wilkins D., Dillinger D.W. The conversion of androstenedione to estrone, estradiol, and testosterone in human breast tissue. J. Steroid Biochem. 13:1980;89-94.
40. Dao T.L., Hayes C., Libby P.R. Steroid sulfatase activities in human breast tumors. Proc. Soc. Exp. Biol. Med. 146:1974;381-384.
41. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre and postmenopausal breast cancer. J. Clin. Endocr. Metab. 81:1996;1460-1464.
42. Chetrite G.S., Pasqualini J.R. The selective estrogen enzyme modulator (SEEM) in breast cancer. J. Steroid Biochem. Mol. Biol. 76:2001;95-104.
43. Blankenstein M.A., van de Ven J., Maitimu-Smeele I., Donker G.H., de Jong P.C., Daroszewski J., Szymaczak J., Milewicz A., Thijssen J.H.H. Intratumoral levels of estrogens in breast cancer. J. Steroid Biochem. Mol. Biol. 69:1999;293-297.
44. Khan S.A., Rogers M.A., Obando J.A., Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res. 54:1994;993-997.
45. Shoker B.S., Jarvis C., Clarke R.B., et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am. J. Pathol. 155:1999;1811-1815.
46. Hall J.M., McDonnell D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and anti-estrogens. Endocrinology. 140:1999;5566-5578.
47. Speirs V., Parkes A.T., Kerin M.J., Walton D.S., Carleton P.J., Fox J.N., et al. Coexpression of estrogen receptor α and β poor prognostic factors in human breast cancer. Cancer Res. 59:1999;525-528.
48. Jackisch C, van der Ven J, Thijssen JHH, Schneider HPG. Effects of HRT on Estrogen Metabolism in Normal and Cancerous Breast Tissue, in preparation.
49. van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of androgens in normal and malignant human breast tissue. Cancer Res. 45:1985;2907-2912.
50. Colditz G.A., Stampfer M.J., Willett W.C., et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. J. Am. Med. Assoc. 264:1990;2648-2653.
51. Gambrell D.R. Proposal to decrease the risk and improve the prognosis in breast cancer. Am. Obstet. Gynecol. 150:1984;119-128.
52. Sigelmann-Danieli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer. 79:1999;456-463.
53. Huang C.S., Chern H.D., Chang K.J., Cheng C.W., Hsu S.M., Shen C.Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 59:1999;4870-4885.
54. Hulka B.S. Effect of exogenous estrogen on postmenopausal women: the epidemiologic evidence. Obstet. Gynecol. Surv. 35:(6):1980;389-399.
55. Samsioe G. The endometrium: Effects of estrogen and estrogen-progestogen replacement therapy. Int. J. Fertil. 39:(Suppl. 2):1994;84-92.
56. Genant H.K., Luca J., Weiss S., et al. Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch. Int. Med. 157:1997;2609-2615.
57. Notelovitz M., Varner R.E., Rebar R.W., et al. Minimal endometrial proliferation over a 2-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menopause. 4:1997;80-88.
58. The Esclim Study Group, Utian W.H., Burry K.A., Archer D.F., Gallagher J.C., Boyett R.L., Guy M.P., Tachon G.J., Chadha-Boreham H.K., Bouvet A.A. Efficacy and safety of low, standard, and high dosage of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. Am. J. Obstet. Gynecol. 181:1999;71-79.
59. Schneider H.P.G., Birkhäuser M. Does HRT modify risk of gynecological cancers. Int. J. Fertil. 40:(Suppl. 1):1995;40-53.
60. Whitehead M.I., Hillard T.C., Crook D. The role and use of progestogens. Obstet. Gynecol. 75:1990;59-76.
61. Sturdee DW, et al. Abstract. Seventh international congress on the menopause, Stockholm, 1993.
62. Gusberg S.B. The individual at high-risk for endometrial carcinoma. Obstet. Gynecol. 126:1976;535-542.
63. Gambrell R.D. Jr. Estrogens, progestogens and endometrial cancer. J. Reprod. Med. 18:1977;301-306.
64. Gambrell R.D. Jr. Prevention of endometrial cancer with progestogens. Maturitas. 8:1986;159-168.
65. Gambrell R.D. Jr, Massey F.M., Castaneda T.A., et al. Use of progestogen challenge test to reduce the risk of endometrial cancer. Obstet. Gynecol. 55:1980;732-738.
66. Fletcher R., Kaufman R.H. Endometrial adenocarcinoma in Stein-Leventhal syndrome. Cancer. 34:1974;444-452.
67. Creasman W.T., Henderson D., Hinshaw W., Clarke-Pearson D.L. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet. Gynecol. 67:1986;326-330.
68. Lee R.B., Burke T.W., Park R.C. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Obstet. Gynecol. 67:1990;326-330.
69. Chapman J.A., Berman M.L., Gelotte D.L., Roth P.D., Osann K., DiSaia P.K. Estrogen replacement therapy in surgical stage I and II endometrial cancer survivors. Am. J. Obstet. Gynecol. 175:1996;1195-1200.
70. Baker D.D. Estrogen replacement therapy in patients with previous endometrial carcinoma. Comp. Ther. 16:1990;28-35.
71. Bryant G.W. Administration of estrogen to patients with a previous diagnosis of endometrial adenocarcinoma. South Med. J. 83:1990;725-726.
72. Beresford S.A.A., Weiss N.S., Voigt L.F., McKnight W. Risk of endometrial cancer in relation to estrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet. 349:1997;458-461.
73. Persson I., Adami H.-O., Bergqvist L., et al. Risk of endometrial cancer after treatment with estrogen alone or in conjunction with progestogens. Br. Med. J. 298:1989;147-151.
74. Greene M.H., Clark J.W., Blayney D.W. The epidemiology of ovarian cancer. Semin. Oncol. 11:1984;209.
75. Collaborative Ovarian Cancer Group, Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II: Invasive epithelial ovarian cancers in white women. Am. J. Epidemiol. 136:1992;1184.
76. Vessey M.P., Painte R. Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br. J. Cancer. 71:1995;1340.
77. Rosenberg L., Palmer J.R., Zauber A.G., Warshauer M.E., Lewis J.L. Jr, Strom B.L., Harlap S., Shapiro S. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am. J. Epidemiol. 139:1994;654.
78. Gross T.P., Schlesselman J.J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet. Gynecol. 83:1994;419.
79. Hereditary Ovarian Cancer Clinical Study Group, Narod S.A., Risch H., Moslehi R., Dørum A., Neuhausen S., Olsson H., Provencher D., Radice P., Evans G., Bishop I.-S., Brunet J.S., Ponder B.A.J. Oral contraceptives and the risk of hereditary ovarian cancer. New Engl. J. Med. 339:1998;424.
80. Fathalla M.F. Incessant ovulation - a factor in ovarian neoplasia. Lancet. ii:1971;163.
81. SHARE Study Group, Ness R.B., Grisso J.A., Klapper J., Schlesselman J.J., Silberzweig S., Vergona R., Morgan M., Wheeler J.E. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am. J. Epidemiol. 152:2000;233.
82. Burger C.W., Koomen I., Peters N.A.J.B., van Leeuwen F.E., Kenemans P. Postmenopausal hormone replacement therapy and cancer of the female genital tract and the breast. Eur. Menopause J. 4/1:1997;23.
83. Kaufman D.W., Kelly J.P., Welch W.R., Rosenberg L., Stolley P.D., Warshauer M.E., Lewis J., Woodruff J., Shapiro S. Noncontraceptive estrogen use and epithelial ovarian cancer. Am. J. Epidemiol. 130:1989;1142.
84. Survey of Women's Health Study Group, Purdie D., Green A., Bain C., Siskind V., Ward B., Hacker N., Quinn M., Wright G., Russel P., Susil B. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Int. J. Cancer. 62:1985;678.
85. Collaborative Ovarian Cancer Group, Harris R., Whittemore A.S., Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am. J. Epidemiol. 136:1992;1204.
86. Negri E., Tzonou A., Beral V., Lagiou P., Trichopoulos D., Parazzini F., Franceschi S., Booth M., La Vecchia C. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int. J. Cancer. 80:1999;848.
87. Rodriguez C., Alpa V.P., Calle E.E., Jacob E.J., Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J. Am. Med. Assoc. 285:2001;1460.
88. Colombo N., Chiari S., Maggioni A., Bocciolone L., Torri V., Maggioni C. Controversial issues in the management of early ovarian epithelial cancer: conservative surgery and role of adjuvant therapy. Gynecol. Oncol. 55:1994;47.
89. Eeles R.A., Tan S., Wiltshaw E., et al. Hormone replacement therapy and survival after surgery for ovarian cancer. Br. Med. J. 302:1991;259.
90. Coughlin S.S., Giustozzi A., Smith S.J., Lee N.C. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J. Clin. Epidemiol. 53:2000;367.